Ketamine is a prescription-only medicine that may be prescribed off-label by our medical team following a comprehensive assessment to assist in the psychotherapy.
Ketamine is a prescription-only medicine that may be prescribed off-label by our medical team following a comprehensive assessment to assist in the psychotherapy.
THE EVIDENCE BASE
Ketamine has been studied across randomised trials, meta-analyses, neuroimaging research and real-world clinical settings. The findings are strongest in treatment-resistant depression, while research into trauma, anxiety, addiction and ketamine-assisted psychotherapy continues to develop.
This page looks at what the evidence supports, where its limits remain, and how current research informs assessment, treatment and integration at The Emerge Clinic.
Peer-reviewed research
Evidence translated into practice
Strengths and limitations stated clearly
THE CURRENT PICTURE
Research on ketamine has grown rapidly over the past two decades. The evidence is strongest in some areas, more limited in others. This page summarises what is well established, what is still developing, and where uncertainties remain.
STRONGEST EVIDENCE BASE
Ketamine has been studied most extensively in people whose depression has not responded sufficiently to conventional treatment. Trials and meta-analyses consistently report rapid reductions in depressive symptoms in a substantial proportion of patients.
CONSISTENT CLINICAL FINDING
Unlike conventional antidepressants, which often take weeks, ketamine can produce noticeable changes within hours or days in some people. This rapid timescale is one of the most replicated findings in the literature.
PROMISING, BUT VARIABLE
A course of treatment often produces stronger and more sustained benefits than a single administration. However, relapse remains common, and the best long-term maintenance approach is still being established.
DEVELOPING EVIDENCE
Research into ketamine-assisted psychotherapy is growing, with encouraging findings across depression, trauma and addiction. The evidence is less mature than the research on ketamine as a medical treatment, and larger controlled studies are still needed.
The evidence is not equally strong across every condition, route of administration or treatment model. That distinction matters.
HOW THE EVIDENCE HAS EVOLVED
Early studies asked whether ketamine could produce a rapid antidepressant response — and they did. Over time, the focus of research has become more clinically useful: who responds, how treatment should be delivered, how long benefits last, what repeated sessions add, and whether psychotherapy helps people make better use of the period that follows treatment.
Early controlled studies showed depressive symptoms could improve much faster than with conventional antidepressants.
Research then focused on people who had already tried established treatments without sufficient relief.
Studies began examining treatment courses rather than single administrations, including response, relapse, and maintenance
Research explored glutamate, synaptic connectivity, neuroplasticity and changes in networks involved in rumination.
The field now increasingly examines preparation, therapeutic support and integration.
“The central question is no longer simply ‘Does ketamine work?’ It is ‘For whom, under what conditions, and how can its benefits be used most effectively?”
The research journey has moved from proving that ketamine can create a rapid response to understanding how that response can be used safely, responsibly and therapeutically.
THE MAJOR FINDINGS
Decades of research now give us a clear set of insights that have reshaped both science and clinical practice. These findings are not simply academic — they are what the evidence has consistently shown.
Change can occur on a very different timescale.
Research has repeatedly found that ketamine can reduce depressive symptoms within hours or days in some people, including those who have not responded sufficiently to conventional antidepressants. This does not mean everyone responds rapidly, or that an early response will necessarily last. But the speed of effect fundamentally changed assumptions about how quickly severe depression could begin to improve.
Often several weeks
Changes may emerge within hours or days
A substantial part of the evidence involves people who have already tried several recognised treatments. Ketamine’s effects in this population are important because they show that a lack of response to previous treatment does not necessarily mean that depression is untreatable.
A single administration can produce a rapid response, but benefits often diminish over time. Research into repeated treatment shows that a carefully planned course can strengthen and extend the response, although the best maintenance strategy remains uncertain.
Ketamine affects glutamate signalling, synaptic connectivity and neuroplasticity. These changes may temporarily reduce the rigidity of established patterns, creating conditions in which new learning and psychological work become easier.
The importance of ketamine is not simply that it may work quickly. It is that it has forced psychiatry to reconsider what may still be possible when conventional treatment has not been enough.
THE LIMITS OF THE EVIDENCE
Ketamine research is encouraging, but it is not complete. Studies use different doses, routes of administration, treatment schedules and outcome measures. Some follow people for hours or days; others for weeks or months. These differences matter when interpreting headline response rates or deciding what the findings may mean for one individual.
Rapid improvement is well established in some patients, but durability varies. Some people maintain gains for weeks or months; others relapse sooner. The best long-term maintenance strategy is still being studied.
Research has not yet identified reliable biomarkers that predict response for an individual patient. Diagnosis, treatment history, biology, psychological state and the treatment setting all likely play a role.
The clinical rationale for preparation and integration is strong, and observational studies are encouraging. However, controlled research isolating exactly how much psychotherapy adds to ketamine’s effects remains less developed.
Evidence from intravenous ketamine cannot automatically be applied to intramuscular, oral or intranasal treatment. Nor can findings from isolated medical administration be assumed to apply directly to psychotherapy-led programmes.
“Uncertainty is not a reason to ignore the evidence. It is a reason to use it carefully.”
At Emerge, research guides treatment, but it never replaces individual assessment, clinical judgement or honest discussion about suitability and expectations.
HOW RESEARCH SHAPES OUR CARE
At The Emerge Clinic, research informs every stage of the programme — from who is considered suitable, to how treatment is prescribed, delivered, supported and reviewed. We do not follow research mechanically or treat every patient as though the same protocol will suit them. The evidence provides a framework. Clinical judgement, psychological formulation and the individual person determine how that framework is applied.
Research informs who may benefit — and who may be at greater risk. Medical history, psychiatric history, current medication and psychological readiness are reviewed before treatment is considered.
We use intramuscular treatment deliberately. IM ketamine offers reliable absorption, a defined treatment window and the clinical control needed for an in-person psychotherapy-led programme.
The medicine is not treated as the whole intervention. Preparation, therapeutic support and integration are built around every session so that any changes in mood, perspective or flexibility can be understood and put to use.
Dosing is individual, not automatic. Published protocols provide a starting framework, but the prescribing clinician considers body weight, medical factors, previous response and tolerability.
Treatment is structured as a course, not a series of isolated appointments. Research into repeated dosing and neuroplasticity informs the spacing of sessions and the time allowed for integration between them.
Further therapeutic work is considered clinically, not commercially. Progress, response, side effects and ongoing need are reviewed before any additional sessions are recommended.
Evidence gives us the map. Clinical judgement tells us how to use it with the person in front of us.
EXPLORE FURTHER
The research below has helped shape current understanding of ketamine’s antidepressant effects, repeated treatment, neurobiology and psychotherapy-assisted approaches. It’s organised to help you follow the evidence from the earliest controlled trials through to newer areas of clinical investigation. Each summary is written in plain language, but these remain technical studies — we encourage you to read the original abstract for full context.
Early studies tested whether ketamine could help people who had not responded sufficiently to established treatments. These studies helped establish that rapid symptom improvement could be achieved even in people who had not responded to previous treatments.
Biological Psychiatry, 2000
Study type: Randomised, double-blind, placebo-controlled crossover study
This early controlled study found that depressive symptoms improved more with ketamine than placebo in people with treatment-resistant depression, with a rapid onset of effect.
Important limitation: Small sample size and short-term follow-up.
Archives of General Psychiatry, 2006
Study type: Randomised, double-blind, placebo-controlled crossover study
Confirmed rapid antidepressant effects of a ketamine infusion within hours of treatment, with response continuing to emerge over the following days, in a placebo-controlled design.
Important limitation: Findings from intravenous administration cannot automatically be extended to other routes.
American Journal of Psychiatry, 2013
Study type: Randomised controlled trial, two-site
This larger, two-site trial replicated earlier findings, strengthening confidence in ketamine’s antidepressant effects and helping establish the reproducibility of the findings across settings.
Important limitation: The study focused on intravenous ketamine and short-term response.
What these studies established: ketamine can produce a rapid antidepressant response in some people whose depression has not improved sufficiently through conventional treatment.
Once rapid response was established, research turned to whether repeated treatment could sustain and extend that response over time.
Open-label study
Study type: Small, open-label, repeated-dose trial
Participants received a series of intravenous ketamine infusions. The overall response rate at the end of treatment was encouraging.
Important limitation: No control group, and a highly selected participant population.
Open-label study
Study type: Open-label, repeated-infusion study
Participants received up to six infusions over 12 days. Response was cumulative for some, with response rates increasing across the treatment course.
Important limitation: No placebo or active-control group during the repeated-dose phase.
Randomised controlled trial
Study type: Randomised crossover study with single, repeated and maintenance phases
This study examined single, repeated and maintenance dosing phases, finding that repeated infusions extended response duration compared with a single dose.
Important limitation: The initial phase was randomised and controlled, but later maintenance phases were less tightly controlled.
Rapid response and lasting benefit are not the same question. The research increasingly treats them separately.
Ketamine research has also examined what may be happening biologically when symptoms change. Human studies increasingly complement earlier animal research, although the underlying mechanisms are not yet completely understood.
Human biomarker study
Study type: Human biomarker study
This study measured blood BDNF levels before and after ketamine treatment and found associations between changes in BDNF and clinical response.
Important limitation: BDNF measured in the blood may not directly reflect changes within the central nervous system.
Neuroimaging study
Study type: Neuroimaging study combining biomarker and functional connectivity data
Using advanced MRI methods, this study found network-level changes that may reflect synaptic and connectivity changes within the prefrontal cortex.
Important limitation: Small sample sizes are common in neuroimaging studies of this kind, and findings need replication.
Randomised controlled trial
Study type: Randomised controlled trial pairing neuroimaging with clinical outcomes
This study found that measurable brain changes can occur within 24 hours and may be associated with subsequent clinical improvement.
Important limitation: Causality cannot be established from correlational imaging findings alone.
Ketamine’s effects are not limited to temporary changes in mood. Treatment may influence neurotrophic signalling.
The evidence for ketamine alone is more mature than the evidence for ketamine-assisted psychotherapy. The studies below are among the early efforts to understand how psychological support and integration change outcomes.
Observational study
Study type: Multi-practice observational study
This study collected outcome data across multiple practices administering ketamine with psychotherapy and found improvements across a broad range of patients.
Important limitation: As an observational design without a control group, it cannot isolate the specific contribution of psychotherapy.
Randomised proof-of-concept trial
Study type: Randomised proof-of-concept trial
This trial paired ketamine with structured CBT to test whether therapy could help sustain response, finding preliminary evidence that responders receiving therapy maintained gains longer than those receiving ketamine alone.
Important limitation: The sample size was modest.
Observational study
Study type: Observational study of patients receiving ketamine-assisted psychotherapy
This study reported sustained improvement across depression and anxiety symptoms, with improvement observed in most people in the sample.
Important limitation: As an uncontrolled observational study, it cannot determine how much of the benefit is attributable to psychotherapy itself.
Preparation, psychological support and integration are clinically plausible and increasingly supported by observational and early controlled research. Larger, well-controlled studies are still needed to isolate exactly what psychotherapy contributes beyond ketamine alone.
This library represents a selected evidence base rather than every published paper. It should be reviewed periodically as larger trials, longer-term follow-up studies and new research into ketamine-assisted psychotherapy become available.
Most foundational ketamine research has examined intravenous administration. Findings from intravenous studies cannot automatically be applied to intramuscular treatment or to psychotherapy-led programmes. Study populations, dosing schedules, outcome measures and follow-up periods also vary substantially.
FROM RESEARCH TO YOUR SITUATION
The studies on this page describe patterns across groups of patients. They cannot determine how one individual will respond, whether ketamine-assisted psychotherapy is suitable, or what form of care would be most appropriate.
That is why every enquiry begins with careful medical and psychological assessment, an honest discussion of expectations and a clear explanation of the available options. If you have read this far and would like to discuss your own situation, the next step is a confidential conversation with Paul.